Roquefort Therapeutics plc (LON:ROQ – Get Free Report) shares dropped 4.1% during mid-day trading on Monday . The company traded as low as GBX 3.55 ($0.05) and last traded at GBX 3.55 ($0.05). Approximately 199,496 shares changed hands during mid-day trading, a decline of 35% from the average daily volume of 308,529 shares. The stock had previously closed at GBX 3.70 ($0.05).
Roquefort Therapeutics Price Performance
The company has a market capitalization of £4.58 million, a PE ratio of -370.00 and a beta of 0.05. The firm has a fifty day moving average of GBX 3.69 and a two-hundred day moving average of GBX 4.26. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.
About Roquefort Therapeutics
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
Further Reading
- Five stocks we like better than Roquefort Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Is Spotify Stock Poised to Soar? Options Traders Think So
- Using the MarketBeat Dividend Yield Calculator
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What Is WallStreetBets and What Stocks Are They Targeting?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.